Together with our partner Brain Research Center, we presented the webinar:
Innovative Endpoints in Alzheimer’s Disease Clinical Trials.
During this webinar, which has been hosted by Thea Wesseling, two experts in the field: Dr. Niels Prins and Dr. Jort Vijverberg gave their thoughts on how we advance clinical drug development for Alzheimer’s disease by touching upon:
> Biomarker-based participant selection in AD trials
> Fluid biomarkers as endpoints in AD trials
> EEG; a ‘novel’ AD biomarker